Impedimetric aptamer-based glycan PSA score for discrimination of prostate cancer from other prostate diseases

Prostate specific antigen (PSA) is the common biomarker for prostate cancer (PCa). However, its lack of specificity to differentiate PCa from benign disorders stimulates search alternative biomarkers improve clinical management patients. Different studies have described changes in core-fucosylation level PSA between patients and healthy controls. To exploit these findings, we adapted an impedimetric aptamer-based sensor dual recognition PSA. Two different aptamers, PSAG-1 anti-PSA, are immobilized onto two adjacent nanostructured gold electrodes. The direct binding diluted serum samples glycosylated-PSA first total second one leads charge transfer resistance, which correlate amount glycosylated sample. sensors able measure with a dynamic range 0.26 62.5 ng/mL (PSAG-1) 0.64 (anti-PSA), reproducibility 5.4 %. final output proposed platform ratio reactive PSA, defined as glycan score. score was tested pathologies, showing excellent correlation measured known diagnosis Hence this biosensor could be used minimally invasive method cancer.